MaxCyte Inc. (MXCT)
NASDAQ: MXCT
· Real-Time Price · USD
2.35
0.07 (3.07%)
At close: Jun 04, 2025, 12:27 PM
3.07% (1D)
| Bid | 2.3 |
| Market Cap | 249.85M |
| Revenue (ttm) | 37.68M |
| Net Income (ttm) | -41.79M |
| EPS (ttm) | -0.4 |
| PE Ratio (ttm) | -5.87 |
| Forward PE | -6.66 |
| Analyst | Buy |
| Ask | 2.4 |
| Volume | 436,065 |
| Avg. Volume (20D) | 890,784 |
| Open | 2.30 |
| Previous Close | 2.28 |
| Day's Range | 2.25 - 2.35 |
| 52-Week Range | 2.10 - 5.26 |
| Beta | 1.13 |
About MXCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MXCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MXCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+11.59%
MaxCyte shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago
+15.83%
MaxCyte shares are trading higher after the company raised its FY24 core revenue guidance and announced layoffs to save $5.8 million per year.
2 months ago · seekingalpha.com
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share PriceMaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by th...
